Publication: Pharmacological effects of chatuphalatika in hyperuricemia of gout
Issued Date
2018-01-01
Resource Type
ISSN
17445116
13880209
13880209
Other identifier(s)
2-s2.0-85046831580
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Pharmaceutical Biology. Vol.56, No.1 (2018), 76-85
Suggested Citation
Vilasinee Hirunpanich Sato, Bunleu Sungthong, Prasob Orn Rinthong, Narawat Nuamnaichati, Supachoke Mangmool, Savita Chewchida, Hitoshi Sato Pharmacological effects of chatuphalatika in hyperuricemia of gout. Pharmaceutical Biology. Vol.56, No.1 (2018), 76-85. doi:10.1080/13880209.2017.1421235 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/45310
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Pharmacological effects of chatuphalatika in hyperuricemia of gout
Other Contributor(s)
Abstract
© 2018 The Author(s). Context: Chatuphalatika (CTPT), is a Thai herbal formulation mixture of Phyllanthus emblica Linn. (Euphorbiaceae), Terminalia belerica Linn. (Combretaceae), T. chebula and the fruit of T. arjuna (Roxb.) Wight & Arn. CTPT is considered to exert anti-inflammatory and antihyperuricemic effects, but there have been no reports to demonstrate these pharmacological effects in a quantitative manner. Objectives: To investigate the antioxidative, anti-inflammatory and antihyperuricemic effects of CTPT. Materials and methods: Antioxidant activities of CTPT extracts were measured in vitro by DPPH, ABTS and FRAP assays, and anti-inflammatory effect by measuring inflammatory mediator production induced by lipopolysaccharide (LPS) in RAW264.7 macrophages. The mechanism of the hypouricemic effect was investigated using oxonate-induced hyperuricemic ddY mice treated with oral administrations of CTPT at 250, 500 and 1000 mg/kg. Results: Antioxidant activities of CTPT measured by ABTS and FRAP assays were 1.35 g TEAC/g extract and 10.3mmol/100 g extract, respectively. IC50 for the inhibition of DPPH radical was 13.8 µg/mL. CTPT (10 µg/mL) significantly downregulated the mRNA expression of TNF-α and iNOS in RAW 264.7 cells. Lineweaver-Burk analysis of the enzyme kinetics showed that CTPT inhibited xanthine oxidase (XOD) activity in a noncompetitive manner with the Ki of 576.9 µg/mL. Oral administration of CTPT (1000 mg/kg) significantly suppressed uric acid production by inhibiting hepatic XOD activity, and decreased plasma uric acid levels in hyperuricemic mice by approximately 40% (p<0.05). Conclusions: This study demonstrated for the first time the antioxidative, anti-inflammatory and antihyperuricemic effects of CTPT in vivo and in vitro, suggesting a possibility of using CTPT for the treatment of hyperuricemia in gout.